The Ebola virus is likely to be eradicated once for all as a new vaccine developed against the disease by Public Health Agency of Canada has shown 100 % efficiency in a trial that was carried out in Guinea.
The preliminary data extracted from the vaccination of 4,000 people suggest that the vaccine “works to protect” humans from the Ebola attack.
Since the epidemic is sporadic, breaking out in a few “hotspots” of West Africa, the trial was jointly performed by Guinean authorities, WHO, Medecins Sans Frontieres (MSF) and Norwegian Institute of Public Health.
A dummy virus (vesicular stomatitis virus, or VSV) was designed with diluted elements of Ebola. As the risk-free virus enters a human body, it alarms the immune system, which launches a scathing attack on the intruder, killing it along with the deadly Ebola virus.
Until July 26, about 11,279 people have died from 27, 748 Ebola infected cases in Guinea, Liberia and Sierra Leone.
The scientists have deployed “the ring” vaccination methodology in the vaccine trial, which means, 4000 people who had had a minimum or a maximum contact with 100 diseased persons were vaccinated with VSV.
The scientists observed that the vaccinated community blocked the virus. One person complained about fever, which wasn’t worrying since it subsided naturally.